Utility of circulating tumor cells in stage II colorectal cancer patients undergoing curative resection

• Published in: Translational cancer research 2020-03, Vol.9 (3), p.1487-1494
• Main Authors: Yu, Jun-Hui, Wang, Dong, Jin, Lan, Wang, Jin, Zhao, Xiao-Mu, Wu, Guo-Cong, Yao, Hong-Wei, Yang, Ying-Chi, Zhang, Zhong-Tao
• Format: Article
• Language: English
• Subjects: Original
• ISSN: 2218-676X; 2219-6803
• DOI: 10.21037/tcr.2020.01.37

The aim of this study was to determine whether circulating tumor cells (CTCs) have utility as a prognostic biomarker in stage II colorectal cancer (CRC), as well as a biomarker for the selection of patients for adjuvant chemotherapy. CTCs were detected in peripheral blood samples obtained from 73 stage II CRC patients, using a negative enrichment and immune-fluorescence in situ hybridization (imFISH) staining method. The follow-up time ranged from 3.5 to 35.9 months, and the clinic-pathologic characteristics and recurrence free survival (RFS) were collected and analyzed. Seventy-three stage II CRC patients were included in this study. The positive rate of CTCs was 65.8% in all patients, 87.5% in recurrent patients and 59.6% in no recurrence patients. The mean RFS was 30.6 months for all patients, 28.7 months for CTC-positive patients and 34.0 months for CTC-negative patients (P=0.043). The mean RFS of CTC-positive and CTC-negative patients with adjuvant chemotherapy were not reached, and those without adjuvant chemotherapy were 27.7 and 33.4 months, respectively. The level of CTCs may be an effective prognostic factor to predict RFS in stage II CRC patients, and has potential in selecting stage II CRC patients for adjuvant chemotherapy.